68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors

被引:191
作者
Ambrosini, Valentina [1 ]
Campana, Davide [2 ]
Bodei, Lisa [3 ]
Nanni, Cristina [1 ]
Castellucci, Paolo [1 ]
Allegri, Vincenzo [1 ]
Montini, Gian Carlo [1 ]
Tomassetti, Paola [2 ]
Paganelli, Giovanni [3 ]
Fanti, Stefano [1 ]
机构
[1] Azienda Osped Univ Bologna, Dept Nucl Med, S Orsola M Malpighi Hosp, Bologna, Italy
[2] Azienda Osped Univ Bologna, Dept Internal Med, S Orsola M Malpighi Hosp, Bologna, Italy
[3] European Inst Oncol, Div Nucl Med, Milan, Italy
关键词
Ga-68-DOTANOC; PET/CT; neuroendocrine tumors; clinical impact; LIVER-TRANSPLANTATION; TNM CLASSIFICATION; ENDOCRINE TUMORS; 7TH EDITION; PROPOSAL; TOMOGRAPHY; CARCINOMA; THERAPY;
D O I
10.2967/jnumed.109.071712
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Several authors reported the superiority of Ga-68-DOTANOC PET/CT to conventional imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of a higher number of lesions is not necessarily followed by a modification of disease stage or therapeutic approach. The aim of this study was to assess the impact of Ga-68-DOTANOC PET/CT on the clinical management of NET patients. Methods: The study included 90 patients with pathologic confirmation of NET, CT performed within a month of Ga-68-DOTANOC PET/CT, and a follow-up period of at least 1 y. PET/CT results were compared with CI results. As a standard of reference to finally evaluate PET results, clinical and imaging follow-up data were used. To assess the clinical impact of PET findings, all referring physicians were contacted after PET and asked about how patients were managed. Stage or therapy modifications were independently recorded, and the overall impact was evaluated patient by patient if PET results either affected therapy or caused a change in disease stage. Results: Considering PET/CT and CI concordant cases (47/90 [52.2%]), PET findings affected the therapeutic management in 17 of 47 (36.2%) patients. Although PET did not result in modification of disease stage, Ga-68-DOTANOC detected a higher lesion number in most patients. PET/CT and CI findings were discordant in 42 of 90 (46.7%) patients: PET resulted in a modification of stage in 12 patients (28.6%) and affected the treatment plan in 32 patients (76.2%). PET and CT were both equivocal in 1 patient (1/90). Considering all cases, Ga-68-DOTANOC PET/CT affected either stage or therapy in 50 of 90 (55.5%) patients. The most frequent impact on management (27 patients) was the initiation or continuance of peptide receptor radionuclide therapy, followed by the initiation or continuance of somatostatin analog medical treatment (7 patients) and referral to surgery (6 patients). PET prevented unnecessary surgery in 6 patients and excluded from treatment with somatostatin analogs 2 patients with NET lesions that did not express somatostatin receptors. Less frequent impacts on management included the initiation of radiotherapy (1 patient), further diagnostic investigation (1 patient), and liver transplantation (1 patient). Conclusion: Ga-68-DOTANOC PET/CT either affected stage or caused a therapy modification in more than half the patients, thus confirming the clinical role of PET in the management of NET.
引用
收藏
页码:669 / 673
页数:5
相关论文
共 30 条
[1]   Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome) [J].
Alberini, JL ;
Belhocine, T ;
Hustinx, R ;
Daenen, F ;
Rigo, P .
NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (10) :1081-1086
[2]   Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours [J].
Ambrosini, Valentina ;
Tomassetti, Paola ;
Castellucci, Paolo ;
Campana, Davide ;
Montini, Giancarlo ;
Rubello, Domenico ;
Nanni, Cristina ;
Rizzello, Anna ;
Franchi, Roberto ;
Fanti, Stefano .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (08) :1431-1438
[3]   68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid [J].
Ambrosini, Valentina ;
Castellucci, Paolo ;
Rubello, Domenico ;
Nanni, Cristina ;
Musto, Alessandra ;
Allegri, Vincenzo ;
Montini, Gian Carlo ;
Mattioli, Sandro ;
Grassetto, Gaia ;
Al-Nahhas, Adil ;
Franchi, Roberto ;
Fanti, Stefano .
NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (04) :281-286
[4]   Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? [J].
Antunes, P. ;
Ginj, M. ;
Zhang, H. ;
Waser, B. ;
Baum, R. P. ;
Reubi, J. C. ;
Maecke, H. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (07) :982-993
[5]   Peptide receptor therapies in neuroendocrine tumors [J].
Bodei, L. ;
Ferone, D. ;
Grana, C. M. ;
Cremonesi, M. ;
Signore, A. ;
Dierckx, R. A. ;
Paganelli, G. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (04) :360-369
[6]  
Bohuslavizki KH, 2000, J NUCL MED, V41, P816
[7]  
DiBartolomeo M, 1996, CANCER-AM CANCER SOC, V77, P402, DOI 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO
[8]  
2-4
[9]   Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET [J].
Fanti, Stefano ;
Ambrosini, Valentina ;
Tomassetti, Paola ;
Castellucci, Paolo ;
Montini, Giancarlo ;
Allegri, Vincenzo ;
Grassetto, Gaia ;
Rubello, Domenico ;
Nanni, Cristina ;
Franchi, Roberto .
BIOMEDICINE & PHARMACOTHERAPY, 2008, 62 (10) :667-671
[10]   Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary [J].
Freudenberg, LS ;
Fischer, M ;
Antoch, G ;
Jentzen, W ;
Gutzeit, A ;
Rosenbaum, SJ ;
Bockisch, A ;
Egelhof, T .
MEDICAL PRINCIPLES AND PRACTICE, 2005, 14 (03) :155-160